logo-loader
viewHavn Life

Havn Life Sciences to take its magic-mushroom growing firm public this summer

Havn Life Sciences Inc Co-CEO Susan Chapelle tells Proactive the privately-held Vancouver-based biotechnology company is looking to take its magic mushroom-focused firm public, expecting to launch its IPO this summer.

Chapelle says what's more, the firm is progressing with its research in growing psilocybin mushrooms to help fix the restrictive supply-chain issue some firms conducting clinical studies are facing in this space.

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Algernon Pharmaceuticals begins screening patients for Phase 2 chronic cough...

Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has begun screening patients in Australia for a Phase 2 idiopathic pulmonary fibrosis and chronic cough clinical study with their repurposed drug...

21 hours, 32 minutes ago

2 min read